Core Insights - Company reported record revenue of approximately HKD 6.11 billion for the first half of 2025, with innovative and barrier products accounting for about 51% of total revenue, a year-on-year increase of nearly 15 percentage points [1] - Net profit for the period was approximately HKD 1.17 billion, with a year-on-year revenue growth of about 13% after excluding the impact of centralized procurement and exchange rates [1] - The company achieved significant milestones in its research and development efforts, with total investment in R&D and projects amounting to approximately HKD 1.02 billion, resulting in 38 major milestone advancements [1] Nuclear Medicine Segment - As a leader in nuclear medicine, the company achieved impressive performance in the nuclear medicine oncology diagnosis and treatment sector, generating a record revenue of HKD 420 million, reflecting a year-on-year growth of nearly 106% [1][2] - The product Yttrium-90 microsphere injection (易甘泰®) continues to demonstrate strong market potential, maintaining rapid growth [1][2] - The company received early FDA approval for 易甘泰® for the treatment of unresectable hepatocellular carcinoma (HCC), becoming the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [2] Innovative Products and Clinical Research - The company’s innovative product STC3141 for treating sepsis has successfully reached the endpoint of its Phase II clinical trial in China, representing a potential breakthrough in sepsis treatment [3] - STC3141 is the first global product aimed at re-establishing immune homeostasis for sepsis treatment, with clinical approvals obtained in five countries across three continents [3] - In the respiratory and critical care sectors, the company is advancing several innovative products, including nasal sprays and coenzyme Q10 tablets, which are expected to enhance commercial performance [4] Overall Growth and Competitive Advantage - The company has established a mature technological innovation development system, continuously reinforcing its differentiated advantages across various sectors [4] - The successful commercialization of innovative products is expected to provide ongoing development momentum, enhancing the company's core competitive advantages and creating value for investors [4]
远大医药(00512)公布2025中期业绩：61.1亿港元收入再创新高，多款创新产品放量尽显发展韧性